U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C24H29NO3
Molecular Weight 379.492
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DONEPEZIL

SMILES

COC1=CC2=C(C=C1OC)C(=O)C(CC3CCN(CC4=CC=CC=C4)CC3)C2

InChI

InChIKey=ADEBPBSSDYVVLD-UHFFFAOYSA-N
InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3

HIDE SMILES / InChI
Molecular Formula C24H29NO3
Molecular Weight 379.492
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Donepezil, marketed under the trade name Aricept, is a medication used in the palliative treatment of Alzheimer's disease. Aricept is indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild to moderate Alzheimer’s Disease, as well as in patients with severe Alzheimer’s Disease. Donepezil is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. Donepezil has been tested in other cognitive disorders including Lewy body dementia and Vascular dementia, but it is not currently approved for these indications. Donepezil has also been studied in patients with Mild Cognitive Impairment, schizophrenia, attention deficit disorder, post-coronary bypass cognitive impairment, cognitive impairment associated with multiple sclerosis, and Down syndrome.

CNS Activity

Originator

Approval Year

1996
225
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 6.7 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Approved
8429
ARICEPT

Approved Use

Donepezil hydrochloride orally disintegrating tablets, USP are an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's Disease (1). Donepezil hydrochloride orally disintegrating tablets, USP are indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's disease.

Launch Date

1996
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
34.1 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9839760
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DONEPEZIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
60.5 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9839760
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DONEPEZIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2889.3 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9839760
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DONEPEZIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5051.9 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9839760
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DONEPEZIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
72.7 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9839760
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DONEPEZIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
73.5 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9839760
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DONEPEZIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4.4%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9839760
5 mg 1 times / day steady-state, oral
dose: 5 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DONEPEZIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
4.4%
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9839760
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DONEPEZIL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
175 mg single, transdermal
Dose: 175 mg
Route: transdermal
Route: single
Dose: 175 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/32440098
healthy, 24.9±3.3 years
n = 9
Health Status: healthy
Age Group: 24.9±3.3 years
Sex: M
Population Size: 9
Sources:
https://pubmed.ncbi.nlm.nih.gov/32440098
Sources:
https://pubmed.ncbi.nlm.nih.gov/32440098
175 mg 1 times / 3 days steady, transdermal
Dose: 175 mg, 1 times / 3 days
Route: transdermal
Route: steady
Dose: 175 mg, 1 times / 3 days
Sources:
https://pubmed.ncbi.nlm.nih.gov/32440098
healthy, 24.9±3.3 years
n = 9
Health Status: healthy
Age Group: 24.9±3.3 years
Sex: M
Population Size: 9
Sources:
https://pubmed.ncbi.nlm.nih.gov/32440098
Sources:
https://pubmed.ncbi.nlm.nih.gov/32440098
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
unhealthy, 73.9 years
n = 967
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 73.9 years
Sex: M+F
Population Size: 967
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
Disc. AE: Bradycardia, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Bradycardia (0.7%)
Diarrhea (1.7%)
Nausea (1.9%)
Vomiting (2.9%)
QT interval prolonged (0.4%)
Anorexia (0.3%)
Dizziness (1.1%)
Headache (0.4%)
Somnolence (0.6%)
Syncope (0.2%)
Aggression (0.5%)
Agitation (0.8%)
Confusional state (0.7%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/10466911
unhealthy, 79 years
n = 1
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 79 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10466911
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (1 patient)
Vomiting (1 patient)
Bradycardia (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10466911
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25202036
unhealthy, 80 years
n = 1
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 80 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/25202036
Disc. AE: Myoclonus...
AEs leading to
discontinuation/dose reduction:
Myoclonus (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/25202036
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
unhealthy, adult
n = 315
Health Status: unhealthy
Age Group: adult
Population Size: 315
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
Other AEs: Diarrhea, Nausea...
Other AEs:
Diarrhea (3%)
Nausea (3%)
Vomiting (2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
unhealthy, adult
n = 350
Health Status: unhealthy
Age Group: adult
Population Size: 350
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (<1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Syncope 0.2%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
unhealthy, 73.9 years
n = 967
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 73.9 years
Sex: M+F
Population Size: 967
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
Anorexia 0.3%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
unhealthy, 73.9 years
n = 967
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 73.9 years
Sex: M+F
Population Size: 967
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
Headache 0.4%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
unhealthy, 73.9 years
n = 967
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 73.9 years
Sex: M+F
Population Size: 967
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
QT interval prolonged 0.4%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
unhealthy, 73.9 years
n = 967
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 73.9 years
Sex: M+F
Population Size: 967
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
Aggression 0.5%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
unhealthy, 73.9 years
n = 967
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 73.9 years
Sex: M+F
Population Size: 967
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
Somnolence 0.6%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
unhealthy, 73.9 years
n = 967
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 73.9 years
Sex: M+F
Population Size: 967
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
Bradycardia 0.7%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
unhealthy, 73.9 years
n = 967
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 73.9 years
Sex: M+F
Population Size: 967
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
Confusional state 0.7%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
unhealthy, 73.9 years
n = 967
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 73.9 years
Sex: M+F
Population Size: 967
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
Agitation 0.8%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
unhealthy, 73.9 years
n = 967
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 73.9 years
Sex: M+F
Population Size: 967
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
Dizziness 1.1%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
unhealthy, 73.9 years
n = 967
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 73.9 years
Sex: M+F
Population Size: 967
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
Diarrhea 1.7%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
unhealthy, 73.9 years
n = 967
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 73.9 years
Sex: M+F
Population Size: 967
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
Nausea 1.9%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
unhealthy, 73.9 years
n = 967
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 73.9 years
Sex: M+F
Population Size: 967
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
Vomiting 2.9%
Disc. AE
23 mg 1 times / day steady, oral
Dose: 23 mg, 1 times / day
Route: oral
Route: steady
Dose: 23 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
unhealthy, 73.9 years
n = 967
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 73.9 years
Sex: M+F
Population Size: 967
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf
Page: p. 50
Bradycardia 1 patient
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/10466911
unhealthy, 79 years
n = 1
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 79 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10466911
Nausea 1 patient
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/10466911
unhealthy, 79 years
n = 1
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 79 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10466911
Vomiting 1 patient
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/10466911
unhealthy, 79 years
n = 1
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 79 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10466911
Myoclonus 1 patient
Disc. AE
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/25202036
unhealthy, 80 years
n = 1
Health Status: unhealthy
Condition: Alzheimer disease
Age Group: 80 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/25202036
Vomiting 2%
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
unhealthy, adult
n = 315
Health Status: unhealthy
Age Group: adult
Population Size: 315
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
Diarrhea 3%
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
unhealthy, adult
n = 315
Health Status: unhealthy
Age Group: adult
Population Size: 315
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
Nausea 3%
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
unhealthy, adult
n = 315
Health Status: unhealthy
Age Group: adult
Population Size: 315
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
Diarrhea <1%
Disc. AE
5 mg 1 times / day steady, oral
Recommended
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
unhealthy, adult
n = 350
Health Status: unhealthy
Age Group: adult
Population Size: 350
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:53289
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:53289
ChemicalBook
CB0156314
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0156314
ChemicalBook
CB23334700
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB23334700
ChemicalBook
CB62741796
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB62741796
ChemicalBook
CB73050236
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB73050236
MolPort
MolPort-003-847-014
https://www.molport.com/shop/molecule-link/MolPort-003-847-014
eMolecules
873089
https://www.emolecules.com/cgi-bin/more?vid=873089
PubMed

PubMed

TitleDatePubMed
Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine.
2001
Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
2001
Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder.
2001 Apr
Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease.
2001 Dec
[Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko].
2001 Dec 13
Donepezil for Down's syndrome.
2001 Jan
Efficacy of acetylcholinesterase inhibitors versus nootropics in Alzheimer's disease: a retrospective, longitudinal study.
2001 Jan-Feb
Featured CME topic: dementia. Medication update.
2001 Jul
[Aphasia and dementia].
2001 Jul
Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease.
2001 Jul-Aug
Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation.
2001 Jun 22
Anticholinesterase drugs for alcoholic Korsakoff syndrome.
2001 Mar
Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors.
2001 May
Donepezil in the treatment of opioid-induced sedation: report of six cases.
2001 May
Alzheimer's disease and related disorders.
2001 May
SCH 57790, a selective muscarinic M(2) receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals.
2001 Nov 16
[Risperidone in the ambulatory treatment of behavior disorders in demented patients of Alzheimer's type: a retrospective analysis].
2001 Nov-Dec
Feasibility of vascular dementia treatment with cholinesterase inhibitors.
2002 Feb
How many patients complete an adequate trial of donepezil?
2002 Jan-Mar
Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.
2002 Mar
Donepezil improved the clinical state and quality of life in moderate-to-severe Alzheimer disease.
2002 Mar-Apr
Patents

Patents

08318942
5
08552195
4
20010039275
12
JP2004131469A
4
JP2007091685A
4
JP2007512338A
11
JP2008195714A
4
JP2011246491A
4
JPH11106353A
4

Sample Use Guides

In Vivo Use Guide
Mild to Moderate Alzheimer’s Disease - 5 mg or 10 mg administered once daily Moderate to Severe Alzheim er’s Disease - 10 mg or 23 mg administered once daily A dose of 10 mg once daily can be administered once patients have been on a daily dose of 5 mg for 4 to 6 weeks. A dose of 23 mg once daily can be administered once patien ts have been on a dose of 10 mg once daily for at least 3 months
Route of Administration: Oral
In Vitro Use Guide
Donepezil inhibited freshly prepared human erythrocyte AChE with IC50 22 nM
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:15:49 GMT 2023
Edited
by admin
on Fri Dec 15 16:15:49 GMT 2023
Record UNII
8SSC91326P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DONEPEZIL
HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
D-797
Common Name English
1-BENZYL-4-((5,6-DIMETHOXY-1-INDANON-2-YL)METHYL)PIPERIDINE
Systematic Name English
DONAZ
Brand Name English
5,6-DIMETHOXY-2-((1-(PHENYLMETHYL)-4-PIPERIDINYL)METHYL)-2,3-DIHYDRO-1H-INDEN-1-ONE
Systematic Name English
Donepezil [WHO-DD]
Common Name English
DONEPEZIL [JAN]
Common Name English
donepezil [INN]
Common Name English
(±)-2-((1-BENZYL-4-PIPERIDYL)METHYL)-5,6-DIMETHOXY-1-INDANONE
Systematic Name English
1H-INDEN-1-ONE, 2,3-DIHYDRO-5,6-DIMETHOXY-2-((1-(PHENYLMETHYL)-4-PIPERIDINYL)METHYL)-
Systematic Name English
DONEPEZIL [HSDB]
Common Name English
DONEPEZIL [VANDF]
Common Name English
2,3-DIHYDRO-5,6-DIMETHOXY-2-((1-(PHENYLMETHYL)-4-PIPERIDINYL)METHYL)-1H-INDEN-1-ONE
Systematic Name English
D797
Common Name English
DONEPEZIL [MI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175723
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
WHO-VATC QN06DA02
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
NDF-RT N0000000177
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
WHO-VATC QN06DA52
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
WHO-ATC N06DA52
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
LIVERTOX NBK548197
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
WHO-ATC N06DA53
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
WHO-ATC N06DA02
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
NCI_THESAURUS C47792
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
Code System Code Type Description
RXCUI
135447
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY RxNorm
CAS
120014-06-4
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY
FDA UNII
8SSC91326P
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY
DAILYMED
8SSC91326P
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY
WIKIPEDIA
DONEPEZIL
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY
CHEBI
53289
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY
MESH
C076946
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY
MERCK INDEX
m4738
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY Merck Index
INN
7517
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY
DRUG CENTRAL
946
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY
SMS_ID
100000080761
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY
DRUG BANK
DB00843
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY
IUPHAR
6599
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY
HSDB
7743
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY
ChEMBL
CHEMBL502
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY
EVMPD
SUB06362MIG
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY
NCI_THESAURUS
C66874
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY
EPA CompTox
DTXSID8048317
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY
PUBCHEM
3152
Created by admin on Fri Dec 15 16:15:49 GMT 2023 , Edited by admin on Fri Dec 15 16:15:49 GMT 2023
PRIMARY
Related Record Type Details
Structure of DONEPEZIL HYDROCHLORIDE
SALT/SOLVATE -> PARENT
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
Structure of DONEPEZIL OXALATE
SALT/SOLVATE -> PARENT
ACETYLCHOLINESTERASE HUMAN
TARGET -> INHIBITOR
Related Record Type Details
DONEPEZIL N-OXIDE
METABOLITE -> PARENT
Structure of 5-O-DESMETHYLDONEPEZIL GLUCURONIDE
METABOLITE -> PARENT
Structure of DONEPEZIL N-OXIDE, TRANS-
METABOLITE -> PARENT
Structure of 5-O-DESMETHYL DONEPEZIL
METABOLITE -> PARENT
Structure of 6-O-DESMETHYLDONEPEZIL GLUCURONIDE
METABOLITE -> PARENT
Structure of 6-O-DESMETHYLDONEPEZIL
METABOLITE -> PARENT
Structure of DESBENZYL DONEPEZIL
METABOLITE -> PARENT
Structure of DONEPEZIL N-OXIDE, CIS-
METABOLITE -> PARENT
Related Record Type Details
Structure of 3-HYDROXYDONEPEZIL
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DONEPEZIL OPEN-RING KETO ACID
IMPURITY -> PARENT
Related Record Type Details
Structure of DONEPEZIL
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966